Your browser doesn't support javascript.
loading
Mapping of Metabolic Heterogeneity of Glioma Using MR-Spectroscopy.
Franco, Pamela; Huebschle, Irene; Simon-Gabriel, Carl Philipp; Dacca, Karam; Schnell, Oliver; Beck, Juergen; Mast, Hansjoerg; Urbach, Horst; Wuertemberger, Urs; Prinz, Marco; Hosp, Jonas A; Delev, Daniel; Mader, Irina; Heiland, Dieter Henrik.
Affiliation
  • Franco P; Department of Neurosurgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Huebschle I; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Simon-Gabriel CP; Department of Neurosurgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Dacca K; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Schnell O; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Beck J; Department of Radiology, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Mast H; Department of Neurosurgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Urbach H; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Wuertemberger U; Department of Neurosurgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Prinz M; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Hosp JA; Department of Neurosurgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Delev D; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Mader I; Department of Neuroradiology, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Heiland DH; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Cancers (Basel) ; 13(10)2021 May 17.
Article in En | MEDLINE | ID: mdl-34067701
Proton magnetic resonance spectroscopy (1H-MRS) delivers information about the non-invasive metabolic landscape of brain pathologies. 1H-MRS is used in clinical setting in addition to MRI for diagnostic, prognostic and treatment response assessments, but the use of this radiological tool is not entirely widespread. The importance of developing automated analysis tools for 1H-MRS lies in the possibility of a straightforward application and simplified interpretation of metabolic and genetic data that allow for incorporation into the daily practice of a broad audience. Here, we report a prospective clinical imaging trial (DRKS00019855) which aimed to develop a novel MR-spectroscopy-based algorithm for in-depth characterization of brain lesions and prediction of molecular traits. Dimensional reduction of metabolic profiles demonstrated distinct patterns throughout pathologies. We combined a deep autoencoder and multi-layer linear discriminant models for voxel-wise prediction of the molecular profile based on MRS imaging. Molecular subtypes were predicted by an overall accuracy of 91.2% using a classifier score. Our study indicates a first step into combining the metabolic and molecular traits of lesions for advancing the pre-operative diagnostic workup of brain tumors and improve personalized tumor treatment.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2021 Document type: Article Affiliation country: Germany Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2021 Document type: Article Affiliation country: Germany Country of publication: Switzerland